[go: up one dir, main page]

ES2160485B1 - Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. - Google Patents

Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.

Info

Publication number
ES2160485B1
ES2160485B1 ES009900844A ES9900844A ES2160485B1 ES 2160485 B1 ES2160485 B1 ES 2160485B1 ES 009900844 A ES009900844 A ES 009900844A ES 9900844 A ES9900844 A ES 9900844A ES 2160485 B1 ES2160485 B1 ES 2160485B1
Authority
ES
Spain
Prior art keywords
cosmetic
pharmaceutical compositions
neuronal
compositions containing
exocitosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009900844A
Other languages
English (en)
Other versions
ES2160485A1 (es
Inventor
Mira Maria Clara Blanes
Hernandez M Mercedes Llobregat
Tebar Ana Isabel Gil
Ballester Gregorio J Fernandez
Cases Rosa Maria Planells
Montiel Antonio V Ferrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipotec SA
Original Assignee
Lipotec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8308129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2160485(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipotec SA filed Critical Lipotec SA
Priority to ES009900844A priority Critical patent/ES2160485B1/es
Priority to AU26729/00A priority patent/AU2672900A/en
Priority to BRPI0011152A priority patent/BRPI0011152B8/pt
Priority to AT00905076T priority patent/ATE338062T1/de
Priority to BR0011152-0A priority patent/BR0011152A/pt
Priority to DK00905076.6T priority patent/DK1180524T4/da
Priority to DE60030429T priority patent/DE60030429T3/de
Priority to EP00905076A priority patent/EP1180524B2/en
Priority to US10/030,485 priority patent/US7015192B1/en
Priority to PT00905076T priority patent/PT1180524E/pt
Priority to JP2000614281A priority patent/JP4363556B2/ja
Priority to CA2370289A priority patent/CA2370289C/en
Priority to PCT/ES2000/000058 priority patent/WO2000064932A1/es
Publication of ES2160485A1 publication Critical patent/ES2160485A1/es
Publication of ES2160485B1 publication Critical patent/ES2160485B1/es
Application granted granted Critical
Priority to US11/327,952 priority patent/US7473679B2/en
Priority to JP2009144480A priority patent/JP4892037B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Péptidos inhibidores de la exocitosis neuronal, composiciones cosméticas y farmacéuticas que los contienen. El péptido tiene una secuencia de 3 a 30 aminoácidos contiguos procedentes del extremo amino de la proteína SNAP-25 y es útil como inhibidor de la exocitosis neuronal. Las composiciones cosméticas y farmacéuticas comprende dicho péptido; opcionalmente junto con uno o más péptidos procedentes del extremo carboxilo de la SNAP- 25. Las composiciones son adecuadas para el, tratamiento de las arrugas faciales, de la asimetría facial y de trastornos y alteraciones patológicas mediadas por una exocitosis neuronal patológica.
ES009900844A 1999-04-23 1999-04-23 Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. Expired - Fee Related ES2160485B1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
ES009900844A ES2160485B1 (es) 1999-04-23 1999-04-23 Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
US10/030,485 US7015192B1 (en) 1999-04-23 2000-02-18 Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
JP2000614281A JP4363556B2 (ja) 1999-04-23 2000-02-18 ニューロンエキソサイトーシス抑制ペプチドおよび該ペプチドを含有する美容組成物および医薬組成物
AT00905076T ATE338062T1 (de) 1999-04-23 2000-02-18 Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen
BR0011152-0A BR0011152A (pt) 1999-04-23 2000-02-18 Péptidos inibidores da exocitosis neurónica, composições cosméticas e farmacêuticas que os contêm
DK00905076.6T DK1180524T4 (da) 1999-04-23 2000-02-18 Neuronal exocytose-hæmmende peptider og kosmetiske og farmaceutiske sammensætninger indeholdende de nævnte peptider
DE60030429T DE60030429T3 (de) 1999-04-23 2000-02-18 Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen
EP00905076A EP1180524B2 (en) 1999-04-23 2000-02-18 Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
AU26729/00A AU2672900A (en) 1999-04-23 2000-02-18 Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
PT00905076T PT1180524E (pt) 1999-04-23 2000-02-18 Péptidos inibidores da exocitose neuronal e composições cosméticas e farmacêuticas que os contêm
BRPI0011152A BRPI0011152B8 (pt) 1999-04-23 2000-02-18 peptídeos inibidores da exocitose neuronal, mistura de peptídeos, composições cosméticas e farmacêuticas, utilização de um peptídeo, e, método para o tratamento cosmético em um ser humano das rugas faciais e/ou da assimetria facial
CA2370289A CA2370289C (en) 1999-04-23 2000-02-18 Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
PCT/ES2000/000058 WO2000064932A1 (es) 1999-04-23 2000-02-18 Peptitos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen
US11/327,952 US7473679B2 (en) 1999-04-23 2006-01-09 Treatments employing neuronal exocytosis-inhibiting peptides
JP2009144480A JP4892037B2 (ja) 1999-04-23 2009-06-17 ニューロンエキソサイトーシス抑制ペプチドおよび該ペプチドを含有する美容組成物および医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009900844A ES2160485B1 (es) 1999-04-23 1999-04-23 Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.

Publications (2)

Publication Number Publication Date
ES2160485A1 ES2160485A1 (es) 2001-11-01
ES2160485B1 true ES2160485B1 (es) 2002-05-16

Family

ID=8308129

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009900844A Expired - Fee Related ES2160485B1 (es) 1999-04-23 1999-04-23 Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.

Country Status (12)

Country Link
US (2) US7015192B1 (es)
EP (1) EP1180524B2 (es)
JP (2) JP4363556B2 (es)
AT (1) ATE338062T1 (es)
AU (1) AU2672900A (es)
BR (2) BRPI0011152B8 (es)
CA (1) CA2370289C (es)
DE (1) DE60030429T3 (es)
DK (1) DK1180524T4 (es)
ES (1) ES2160485B1 (es)
PT (1) PT1180524E (es)
WO (1) WO2000064932A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
CA2797652C (en) 2000-07-21 2016-03-08 Revance Therapeutics, Inc. Multi-component biological transport systems
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
FR2846885B1 (fr) * 2002-11-13 2004-12-24 Oreal Utilisation d'une association de composants a effet synergique inhibiteur de canaux calciques pour prevenir ou traiter les ridules
US7071167B2 (en) 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
JP2004323400A (ja) * 2003-04-23 2004-11-18 Mikimoto Pharmaceut Co Ltd 皮膚外用剤
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2005251676B2 (en) 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
PT1729821E (pt) 2004-03-03 2013-10-23 Revance Therapeutics Inc Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US7964630B2 (en) 2004-11-02 2011-06-21 Dsm Ip Assets B.V. Topical application agents against mimic and age-related wrinkles
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
US8022179B2 (en) * 2005-03-03 2011-09-20 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
ES2259928B1 (es) * 2005-04-08 2007-11-01 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica que comprende peptidos derivados de encefalinas para reducir y/o eliminar arrugas faciales.
WO2007059528A2 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
WO2007071448A2 (en) * 2005-12-23 2007-06-28 Partnership & Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
ES2322882B1 (es) * 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
EP1992332A1 (en) 2007-05-08 2008-11-19 Tupperware Products S.A. Cosmetic anti ageing skin care compositions
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
EP2456457B1 (en) 2009-07-24 2014-10-22 Lipotec, S.A. Compounds which inhibit muscle contraction
US20110305735A1 (en) * 2010-06-09 2011-12-15 Lipotec, S.A. Skin antiaging treatment
US20130078295A1 (en) * 2010-06-09 2013-03-28 Lipotec S.A. Skin antiaging treatment
ES2385683B1 (es) * 2010-10-18 2013-10-07 Bcn Peptides, S.A. Composiciones para el tratamiento del dolor y/o la inflamación.
US9248089B2 (en) 2011-11-07 2016-02-02 Grf (Wuhan) Biotechnology Inc. Peptide-based compounds as inhibitors of neurotransmitter secretion
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
ES2678793T3 (es) 2012-04-13 2018-08-17 Activen Composición cosmética que comprende un muconopéptido
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
US10149812B2 (en) 2012-04-13 2018-12-11 Activen Cosmetic composition comprising a muconopeptide
CA2928526A1 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
KR102481341B1 (ko) 2014-10-31 2022-12-23 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 피부 표면으로 활성 작용제의 전달을 위한 열가소성 폴리우레탄 필름
CN104478991B (zh) * 2014-12-10 2018-06-19 深圳市维琪医药研发有限公司 一种新型多肽化合物及其制备方法和其医药应用
CN104829691B (zh) * 2015-05-19 2018-11-02 山西锦波生物医药股份有限公司 除皱短肽及其制备方法
WO2017079248A1 (en) 2015-11-05 2017-05-11 Lubrizol Advanced Materials, Inc. Thermoformable dual network hydrogel compositions
ES2937382T3 (es) 2018-02-27 2023-03-28 Lipotrue S L Péptidos y composiciones para uso en cosmética y medicina
JP7488198B2 (ja) 2018-06-13 2024-05-21 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 神経細胞エキソサイトーシスに対して阻害活性を有するペプチド
US20230190616A1 (en) 2018-08-10 2023-06-22 Lubrizol Advanced Materials, Inc. Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
CN118561963A (zh) 2018-10-16 2024-08-30 格罗制药公司 烟碱乙酰胆碱受体肽拮抗剂芋螺毒素组合物及相关方法
MX2020014330A (es) * 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
EP4144337B1 (en) 2021-09-02 2024-08-07 Guangzhou Jiyan Cosmetics Technology Co. Ltd. Vitis vinifera cosmetic composition
CN113826764B (zh) * 2021-09-24 2024-07-12 江苏三仪生物工程有限公司 一种大豆小肽螯合铁的制备方法
EP4230638A1 (en) 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides and compositions for use in cosmetics
WO2023161264A1 (en) 2022-02-23 2023-08-31 Prospera Biotech, S.L. Compositions for treating hyperhidrosis
WO2023184114A1 (zh) 2022-03-28 2023-10-05 深圳市维琪科技股份有限公司 一种多肽及其美容组合物或药用组合物和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2334897A (en) * 1996-03-18 1997-10-10 Regents Of The University Of California, The Peptide inhibitors of neurotransmitter secretion by neuronal cells
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.

Also Published As

Publication number Publication date
US7473679B2 (en) 2009-01-06
JP2009221223A (ja) 2009-10-01
BR0011152A (pt) 2002-02-19
CA2370289A1 (en) 2000-11-02
DE60030429D1 (de) 2006-10-12
EP1180524A1 (en) 2002-02-20
US7015192B1 (en) 2006-03-21
EP1180524B2 (en) 2010-07-07
EP1180524B1 (en) 2006-08-30
BRPI0011152B8 (pt) 2022-05-10
BRPI0011152B1 (pt) 2018-03-13
PT1180524E (pt) 2007-01-31
JP4363556B2 (ja) 2009-11-11
JP4892037B2 (ja) 2012-03-07
US20060276392A1 (en) 2006-12-07
ATE338062T1 (de) 2006-09-15
DE60030429T2 (de) 2007-10-31
WO2000064932A1 (es) 2000-11-02
ES2160485A1 (es) 2001-11-01
DK1180524T3 (da) 2006-12-11
JP2002542777A (ja) 2002-12-17
AU2672900A (en) 2000-11-10
CA2370289C (en) 2011-04-19
DE60030429T3 (de) 2012-01-12
DK1180524T4 (da) 2010-10-25

Similar Documents

Publication Publication Date Title
ES2160485B1 (es) Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
ES2563677T3 (es) Composiciones de combinaciones de Neisseria
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
PT1200105E (pt) Factor viii modificado
NO20014508D0 (no) Fremgangsmåte for acylering av peptider, og nye acyleringsmidler
AR030307A1 (es) Peptidos de promiostatina y metodos para utilizarlos
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
AR039231A1 (es) Agentes de union ox40r novedosos
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
AR053063A2 (es) Proteina sustancialmente purificada y composicion farmaceutica que la comprende
AR072009A1 (es) Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos
DE60035412D1 (de) Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren
CO2021017664A2 (es) Péptidos
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt
ES2066510T3 (es) Nuevos polipeptidos con afinidad para lipopolisacaridos y sus usos.
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
CO5570658A2 (es) Composicion y metodo para el tratamiento de la diabetes
ES2507094T3 (es) Proteína específica del timo
ES2534752T3 (es) Nuevo péptido antigénico contra el cáncer y utilización del mismo
ES2531480T3 (es) Péptidos derivados de la proteína bplp humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
ES2060134T3 (es) Inhibidor de tejido de metaloproteasas (timp-2).
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20011101

Kind code of ref document: A1

Effective date: 20011101

FD2A Announcement of lapse in spain

Effective date: 20190730